Search clinical trials for: Ciclesonide HFA

Total 1376 results

Sunovion

Completed

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Seasonal Allergic Rhinitis

United States
Sunovion

Completed

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Allergic Rhinitis | Perennial Allergic Rhinitis

United States
AstraZeneca

Completed

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Rhinitis, Allergic, Seasonal

United States
AstraZeneca

Recruiting

Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Compared to HFA MDI Propellant in Healthy Participants

Mucociliary Clearance

United States
Sunovion

Completed

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Perennial Allergic Rhinitis

United States
AstraZeneca

Completed

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Asthma

United States
Sunovion

Completed

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

Perennial Allergic Rhinitis

United States
Wills Eye
Olleyes, Inc.

Completed

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

Glaucoma, Open-Angle

United States
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
Sunovion

Completed

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Jenny Kallunki
Region Östergötland; Malmö University; Eklund foundation Malmö; Swedish Dental...

Active, not recruiting

Treatment of Class II Malocclusion With Excessive Overjet

Quality of Life | Orthodontic Appliances | Class II Malocclusion, Division 1 | Costs and Cost Analysis

Sweden
University of Chicago
Sunovion

Withdrawn

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Allergic Rhinitis

United States
Hamilton Health Sciences Corporation
Takeda; Kolding Sygehus

Completed

Effect of Ciclesonide on Exercise Induced Bronchoconstriction

Asthma

Canada
University Medical Center Groningen
Boston Scientific Corporation

Not yet recruiting

Pulsed Field Ablation Versus Conventional Radiofrequency Catheter Ablation for Repeat PVI in Patients With Paroxysmal AF (REPEAT-AF)

Atrial Fibrillation Recurrent
Texas Christian University

Unknown

Hunger, Satiety, and Metabolic Responses to High-fat Meals of Varying Fatty Acid Composition

Body Weight Changes

United States
Boehringer Ingelheim

Terminated

Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
AstraZeneca

Not yet recruiting

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
Hospital de Clinicas de Porto Alegre
Federal University of Rio Grande do Sul; Coordenação de Aperfeiçoamento de...

Completed

Glycemic and Insulinemic Response With Different Sources of Soluble Fiber in Patients Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2 | Dietary Modification | Insulin Tolerance | Diabetic Blood Glucose Monitoring

Brazil
AstraZeneca
Parexel

Not yet recruiting

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Healthy
Sunovion

Completed

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
Boehringer Ingelheim

Completed

A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
AstraZeneca

Recruiting

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Heathy Participants

United States
West Penn Allegheny Health System

Completed

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Asthma | Allergic Rhinitis

United States
Sunovion

Completed

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Perennial Allergic Rhinitis

United States
Sunovion

Completed

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Sunovion

Completed

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Perennial Allergic Rhinitis | PAR

United States
Allergy & Asthma Medical Group & Research Center

Completed

Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary

Asthma

United States
Sanofi
Takeda

Completed

Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma

Asthma
Sanofi

Completed

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Asthma

United States
Sanofi

Completed

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Asthma

United States, Brazil, Poland, Russian Federation, Estonia, Mexico, Israel, Chile, Latvia, Puerto Rico, Costa Rica
Chiesi Farmaceutici S.p.A.

Recruiting

Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) (TRECOS)

Asthma

United Kingdom
AstraZeneca

Completed

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Rhinitis, Allergic, Perennial | Hay Fever

United States
AstraZeneca

Completed

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Seasonal Allergic Rhinitis | Hay Fever

United States
Rutgers, The State University of New Jersey

Completed

Lean and Obese: Dietary Inflammation (LODI)

Inflammation | Obesity | Dietary Fat

United States
Ola Blennow, MD, PhD
Karolinska University Hospital; Danderyd Hospital; Centrallasarettet Västerås

Active, not recruiting

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (HALT)

Pneumonia, Viral | Covid-19 | Sars-CoV2

Sweden
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

Seasonal Allergic Rhinitis

Russian Federation
Carl Zeiss Meditec, Inc.

Unknown

Glaucoma HFA / OCT Specificity Study

Glaucoma

United States
Sunovion

Completed

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

Perennial Allergic Rhinitis

United States
Amphastar Pharmaceuticals, Inc.

Terminated

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

Asthma | Bronchospasm

United States
MDRC
Johns Hopkins University; Columbia University; University of Georgia; Mathematica... and other collaborators

Active, not recruiting

Mother and Infant Home Visiting Program Evaluation (MIHOPE)

Pregnancy | Infant Development

United States
Amphastar Pharmaceuticals, Inc.

Terminated

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients

Asthma

United States
AstraZeneca

Completed

A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Allergic Rhinitis
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Korea, Republic of, Argentina, Canada, India, Bulgaria, Poland
Korea University Guro Hospital

Completed

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

COVID-19

Korea, Republic of
Sanofi
Takeda

Completed

Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma

Respiratory Tract Diseases | Asthma | Respiratory Hypersensitivity

France
Acessa Health, Inc.

Active, not recruiting

Post Market TRUST - U.S.A. Study

Symptomatic Uterine Fibroids

United States
Apotex Inc.

Completed

A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis
Sunovion

Completed

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis | PAR

United States
Boehringer Ingelheim

Completed

Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects

Healthy

3

Subscribe